MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
18.82
+0.12
+0.64%
After Hours: 19.45 +0.63 +3.35% 16:51 03/31 EDT
OPEN
18.89
PREV CLOSE
18.70
HIGH
19.10
LOW
18.65
VOLUME
1.54M
TURNOVER
0
52 WEEK HIGH
28.06
52 WEEK LOW
12.24
MARKET CAP
3.05B
P/E (TTM)
-14.0752
1D
5D
1M
3M
1Y
5Y
Is CRISPR Therapeutics (CRSP) Stock Outpacing Its Medical Peers This Year?
NASDAQ · 3d ago
SVB Securities Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
TipRanks · 4d ago
Analyst Ratings for ACADIA Pharmaceuticals
Benzinga · 03/20 13:00
JP Morgan Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $21
Benzinga · 03/20 11:34
JPMorgan Chase Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $19, Maintains Neutral Rating
JPMorgan Chase Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $19, Maintains Neutral Rating
MT Newswires · 03/20 09:30
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
NASDAQ · 03/16 15:20
Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?
NASDAQ · 03/15 06:43
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug
Benzinga · 03/14 12:28
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The Company has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The Company also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

Webull offers kinds of ACADIA Pharmaceuticals Inc stock information, including NASDAQ:ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.